I reread Charlie's article tonight and I had overlooked some information.
https://themedicinemaker.com/manufacture/eliminating-bioconjugation-roadblocks
vaccine and drug development !!! Derek said we were only involved in vaccine quality control?
"Confidence in such bioconjugation tools can also be derived from the growing catalog of diagnostic and therapeutic R&D efforts that have been made possible by these novel binding technologies. Adiponectin immunosensor development, tumor cell isolation, and extracellular vesicle research are just a few examples of the research areas benefiting from this approach. "
we have been working on these for a while and have publication on all 3 on our webpage.
https://www.anteotech.com/life-science/anteobind/publications/
why I revisited the article was because I saw this from Merck
Antibody-drug conjugates (ADCs) are an emerging class of medicines designed for high-specificity targeting and destruction of cancer cells while preserving healthy cells.
https://www.linkedin.com/posts/merc...ugates-adcs-activity-6807939340547715072-41jK
then reading the article we have this
"A recent study used the technology to conjugate recombinant Spike RBD of selected SARS-CoV-2 variants. It sought to understand the impact of COVID-19 vaccination on the levels of neutralizing antibodies against these RBD variants, and demonstrated that the nanosized molecular glue approach to bioconjugation provides a rapid and effective tool for SARS-CoV-2 multiplex immunoassay development for vaccine study (1)."
from the study
https://www.medrxiv.org/content/10.1101/2021.03.08.21252958v1
"The SARS-CoV-2 pandemic virus is consistently evolving with mutations within the receptor binding domain (RBD)1 being of particular concern2-4. To date, there is little research into protection offered following vaccination or infection against RBD mutants in emerging variants of concern (UK3, South African5, Mink6 and Southern California7). To investigate this, serum and saliva samples were obtained from groups of vaccinated (Pfizer BNT-162b28), infected and uninfected individuals."
Bead coupling
Coupling of RBD mutant antigens was done by Anteo coupling (#A-LMPAKMM-10, Anteo Tech Reagents) following the manufacturer’s instructions. Briefly, 100 μL of spectrally distinct populations of MagPlex beads (1.25×106) (Luminex) were activated in 100 μL of AnteoBind Activation Reagent for 1 hour at room temperature.
I think management are involved in a lot of projects that we will be hearing about!!! we aren't just relying on our covid test. add batteries, contract services, raw materials ,drug and vaccine development to a growing list of future revenue possibilities.....
- Forums
- ASX - By Stock
- ADO
- Vaccine and Drug Development
Vaccine and Drug Development, page-7
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ADO (ASX) to my watchlist
|
|||||
Last
2.2¢ |
Change
-0.002(6.52%) |
Mkt cap ! $53.07M |
Open | High | Low | Value | Volume |
2.2¢ | 2.2¢ | 2.2¢ | $20.42K | 928.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 1118907 | 2.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.2¢ | 7380 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 1118907 | 0.021 |
13 | 4461723 | 0.020 |
6 | 1464605 | 0.019 |
9 | 2336112 | 0.018 |
4 | 432891 | 0.017 |
Price($) | Vol. | No. |
---|---|---|
0.022 | 7380 | 2 |
0.023 | 899841 | 4 |
0.024 | 225300 | 2 |
0.025 | 1138770 | 9 |
0.027 | 250000 | 1 |
Last trade - 15.45pm 05/09/2024 (20 minute delay) ? |
Featured News
ADO (ASX) Chart |